SHR-A1811 in Combination With Adebrelimab for the Treatment of HER2 Low-expressing Metastatic Breast Cancer - Trial NCT06411457
Access comprehensive clinical trial information for NCT06411457 through Pure Global AI's free database. This Phase 2 trial is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences and is currently Recruiting. The study focuses on Breast Cancer. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Timeline & Enrollment
Phase 2
May 16, 2024
May 01, 2026
Primary Outcome
ORR
Summary
To evaluate the efficacy and safety of the SHR-A1811 in combination with Adebrelimab regimen
 in HER2 low-expressing metastatic breast cancer
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06411457
Non-Device Trial